Fig. 1: Treatment response to CAR-T therapy in R/R B-ALL patients. | Cell Death & Disease

Fig. 1: Treatment response to CAR-T therapy in R/R B-ALL patients.

From: Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients

Fig. 1

CR rate was 92.3%, CR with MRD-negative rate was 76.9%, CR with MRD-positive rate was 15.4%, and bridging to HSCT rate was 43.6% (a). The mean time since infusion to CR was 13.6 ± 7.7 days, and the mean time since infusion to MRD negative was 15.5 ± 8.8 days (b). CR, complete remission; MRD, minimal residual disease; HSCT, hematopoietic stem-cell transplantation.

Back to article page